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Abstract: The use of contralateral risk reducing mastec-
tomy (CRRM) is indicated in women affected by breast 
cancer, who are at high risk of developing a contralateral 
breast cancer, particularly women with genetic mutation 
of BRCA1, BRCA2 and P53. However we should consider 
that the genes described above account for only 20-30% of 
the excess familiar risk. What is contralaterally indicated 
when genetic assessment results negative for mutation in 
a young patient with unilateral breast cancer? Is it ethi-
cally correct to remove a contralateral “healthy” breast? 
CRRM rates continue to rise all over the world although 
CRRM seems not to improve overall survival in women 
with unilateral sporadic breast cancer. The decision to 
pursue CRRM as part of treatment in women who have a 
low-to-moderate risk of developing a secondary cancer 
in the contralateral breast should consider both breast 
cancer individual-features and patients preferences, but 
should be not supported by the surgeon and avoided as 
first approach with the exception of women highly worried 
about cancer. Prospective studies are needed to identify 
cohorts of patients most likely to benefit from CRRM. 
Keywords: Breast Cancer, contralateral risk reducing mas-
tectomy, Non-mutated patients
1  Introduction
Breast cancer represent the second leading cause of can-
cer-related deaths in the United States [1] and the UK [2]. 
Although it regards predominantly older women, approx-
imately 12% of new breast cancer cases occur in women 
younger than 45 years [3]. Younger age is usually related 
with more aggressive and less responsive tumours and 
consequently with lower survival rates, higher recurrence 
rates, and negative prognostic variables [4-6]. Therapeutic 
interventions include chemotherapy, hormone-therapies 
and surgery with or without radiotherapy. Systemic treat-
ments impact on fertility prompting early menopause and 
ovarian decline [7]. Higher depression rates with effect 
on family life are also reported in these patients [8]. Refer 
to surgery could be cause of a negative body image that 
influence post-operative quality of life. Breast surgery 
includes breast conserving surgery (BCS) followed by 
radiation-therapy (RT) for early breast cancer or unilat-
eral mastectomy (UM). BCS with RT and UM survival rates 
are equivalent [9], but preserving the breast, considering 
an oncoplastic technique could achieve better satisfaction 
levels and improve post-operative quality of life. Recently, 
however, numerous papers revealed a consistent growth 
in the use of both UM and contralateral risk reducing mas-
tectomy (CRRM) [10,11]. CRRM consist in a so-called con-
servative mastectomy, the Nipple Areola Complex-Sparing 
Mastectomy that preserve the native breast skin and the 
nipple-areola complex, resulting in improved aesthetic 
results with local recurrence rates comparable to the 
traditional modified radical mastectomy [12]. The use of 
UM and CRRM is indicated in women affected by breast 
cancer, who are at high risk of developing a contralateral 
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breast cancer (CBC), particularly women with genetic 
mutation of BRCA1, BRCA2 and P53. However, we should 
consider that the genes described above account for only 
20–30% of the excess familial risk [13,14]. Consequently, 
the genetic etiology for the majority of families with an 
increased familial breast cancer risk remains unknown. 
Young age at diagnosis is a feature of hereditary disease 
and it is currently suggested that all women diagnosed 
with breast cancer younger than 37 should be referred for 
genetic assessment. But what is indicated in the contralat-
eral breast when genetic assessment results are negative 
for mutation in a young patient with unilateral breast 
cancer? Is it ethically correct to remove a contralateral 
“healthy” breast? 
2  Literature search
We reviewed PubMed database using the keywords “con-
tralateral breast cancer”, “contralateral prophylactic mas-
tectomy” and “contralateral risk reducing mastectomy”. 
We included only articles in English focused on contralat-
eral mastectomy in women who presented a low-to-mod-
erate risk of developing a secondary cancer in the con-
tralateral breast. We considered as low-to-moderate risk 
patients, all women with a unilateral breast cancer in 
young age without a genetic mutation of BRCA1, BRCA2, 
P53 and without an evidence of strong familiarity for 
breast cancer.  All papers reporting BRCA gene mutation 
carriers and other high-risk women have been excluded.
3  Results
Between January 1, 2005 and March 1, 2016 more than 
300 papers were retrieved. Only 10% of retrieved papers 
addressed the impact of contralateral risk reducing mas-
tectomy on overall survival [16-31]. Contralateral risk 
reducing mastectomy is estimated to reduce the risk of 
developing a contralateral breast cancer by approximately 
94% [15]. Some studies showed a disease free survival 
(DSF) benefit associated with CRRM, but not an overall 
survival benefit [25,29].
4  Discussion
As a preventive measure, CRRM in women with low-to-mod-
erate risk of developing a secondary cancer in contralat-
eral breast remains controversial and potential benefits 
and disadvantages need to be discussed. The risk of mor-
tality from contralateral disease must always be weighed 
against risk of mortality from primary tumour metastases, 
without an overall survival benefit. Different studies in 
fact showed as patients prognosis is strongly related to 
the features of their first breast cancer [32-34]. Moreover, 
mastectomy does not remove all breast tissue and there-
fore cannot eliminate risk of breast cancer at all, even if 
this surgery is shown to be effective in reducing risk. Pres-
ently, we are participating in a serious paradox: “a lesser 
surgical procedure is always more used in patients with 
an invasive breast cancer thanks to the screening program 
that allows an early detection of small cancer while mas-
tectomy is offered in healthy breast for cancer preven-
tion [32]”. In addition, there is no demonstrated survival 
benefit [35] and CRRM may cause significant physical mor-
bidity: complication including infection, nipple areola 
complex necrosis, bleeding with a re- operation rate up 
to 16% of patients [36]. Chronic pain and unsatisfactory 
aesthetic results are also been reported respectively up to 
50% and 84% of the CRRM affecting irreparably post-op-
erative quality of life [37,38]. Women should be thoroughly 
informed about achievable outcomes in breast reconstruc-
tive surgery when considering undergoing risk reducing 
procedures. On the other side, CRRM in non affected 
breast have potential benefits connected with the reduc-
tion of both risk of cancer and anxiety patient. Given the 
potential complications and no demonstration of survival 
benefits, CRRM could be safely omitted in patients with 
low-to-moderate breast cancer risk.  
5  Conclusion
CRRM rates continue to rise all over the world although 
CRRM seems not to improve overall survival in women 
with unilateral sporadic breast cancer. The decision to 
pursue CRRM as part of treatment in women who have a 
low-to-moderate risk of developing a secondary cancer 
in the contralateral breast should consider both breast 
cancer individual-features and patients preferences, but 
should not be supported by the surgeon and avoided as 
first line approach with the exception of women highly 
worried about cancer. Prospective studies are needed to 
identify cohorts of patients most likely to benefit from 
CRRM.
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